Loading clinical trials...
Loading clinical trials...
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
NCT06647069 · Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)
NCT07413341 · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), and more
NCT07331272 · Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
NCT07339332 · Systemic Lupus Erythematosus (SLE)
NCT07185269 · Systemic Lupus Erythematosus (SLE)
Local Institution - 0001
Farmington, Connecticut
New York University School Of Medicine
New York, New York
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions